The company is investing more than $35m in the expanded manufacturing and product-handling capabilities
Curia, formerly AMRI, a CDMO, has announced plans to expand its commercial manufacturing capacity at its Rensselaer, New York facility. The increased capability to flexibly manufacture complex APIs will further strengthen the company’s ability to partner with customers, meeting small-scale to large-volume requirements.
The company is investing more than $35m in the expanded manufacturing and product-handling capabilities. It will include additional vessel capacities more than doubling the site’s batch-size scaling and product output. It will also allow for the introduction of additional products and help the company meet growing demand for HPAPI manufacturing.
The expansion will generate technical jobs in Rensselaer and the plans also include optimisation of energy usage and enhanced environmental standards as integral elements, the company claims.
“Our Rensselaer team’s history of excellence in delivering U.S.-based complex manufacturing solutions that enable our customers to provide vital treatments to patients is resulting in increasing demand,” said Curia Chairman and CEO John Ratliff. “Some of the life-saving products produced at Rensselaer are highly complex, including critical oncology therapeutics and novel treatments addressing unmet medical needs. The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”
The site currently produces APIs to meet the development and commercial needs of more than 50 products. The expansion is expected to be completed within 18 months, adding to the company’s existing API manufacturing facilities in the US, France, Spain, Italy and India.